By Dennis Thompson HealthDay ReporterTHURSDAY, March 12, 2026 (HealthDay News) — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the ...

GLP-1 receptor agonists were not associated with recurrence or progression in well differentiated thyroid cancer, supporting ...

Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn't switch, according to ...

Add Yahoo as a preferred source to see more of our stories on Google. The World Health Organization (WHO) has endorsed the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment ...

GLUCAGON-LIKE peptide-1 receptor agonists (GLP-1RA) produce greater weight loss results among women than men, a 2026 ...

(Paris, France, Thursday, 18 September 2025) Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major ...

Adults with chronic migraine using glucagon-like peptide-1 receptor agonists for other conditions are seeking less migraine treatment.

One of the unintended consequences for people seeking weight loss through glucagon-like peptide 1 (GLP-1) receptor agonists is often poor nutrient status, muscle loss, and metabolic dysfunction. That ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Hims & Hers will curb its advertising and compounded offerings, while Novo will drop its lawsuit.

SGLT2i initiation was associated with a 19% lower adjusted risk for CKD and a 12% lower rate of AKI events over 5 years compared to GLP-1RA initiation. Initiation of sodium-glucose co-transporter 2 ...